Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee: response.

Spierings EL, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR.

Pain. 2014 Nov;155(11):2432-3. doi: 10.1016/j.pain.2014.08.038. Epub 2014 Sep 3. No abstract available.

PMID:
25194672
2.

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators.

Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1.

PMID:
25190523
3.

Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results.

Kjeldsen SE, Sica D, Haller H, Cha G, Gil-Extremera B, Harvey P, Heyvaert F, Lewin AJ, Villa G, Mancia G; DISTINCT Investigators.

J Hypertens. 2014 Dec;32(12):2488-98; discussion 2498. doi: 10.1097/HJH.0000000000000331.

4.

Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.

Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M; NAC-MD-01 Study Investigators.

Lancet. 2014 May 31;383(9932):1889-98. doi: 10.1016/S0140-6736(14)60614-0. Erratum in: Lancet. 2016 Sep 24;388(10051):1280.

PMID:
24881993
5.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators.

JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321.

PMID:
24682069
6.

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC; EMPA-REG MONO trial investigators.

Lancet Diabetes Endocrinol. 2013 Nov;1(3):208-19. doi: 10.1016/S2213-8587(13)70084-6. Epub 2013 Sep 9.

PMID:
24622369
7.

Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia.

Spaeth M, Alegre C, Perrot S, Wang Y, Guinta DR, Alvarez-Horine S, Russell I; Sodium Oxybate Fibromyalgia Study Group.

Arthritis Res Ther. 2013 Nov 11;15(6):R185. doi: 10.1186/ar4375.

8.

A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.

Spierings EL, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR.

Pain. 2013 Sep;154(9):1603-12. doi: 10.1016/j.pain.2013.04.035. Epub 2013 Apr 22.

PMID:
23707270
9.

Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial.

Tyring SK, Plunkett S, Scribner AR, Broker RE, Herrod JN, Handke LT, Wise JM, Martin PA; Valomaciclovir Zoster Study Group.

J Med Virol. 2012 Aug;84(8):1224-32. doi: 10.1002/jmv.23329.

PMID:
22711350
10.

Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial.

Pattzi HM, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, Cherrington JM, Guler HP; PHX1149-PROT202 Study Group.

Diabetes Obes Metab. 2010 Apr;12(4):348-55. doi: 10.1111/j.1463-1326.2010.01195.x.

PMID:
20380656
11.
12.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators.

N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.

13.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group.

Curr Med Res Opin. 2009 Oct;25(10):2361-71. doi: 10.1185/03007990903156111.

PMID:
19650752
14.

Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.

Chrysant SG, Neutel JM, Ferdinand KC; INCLUSIVE investigators.

J Natl Med Assoc. 2009 Apr;101(4):300-7.

PMID:
19397219
15.

Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.

Lacourcière Y, Wright JT Jr, Samuel R, Zappe D, Purkayastha D, Black HR; EVALUATE study.

Blood Press Monit. 2009 Jun;14(3):112-20. doi: 10.1097/MBP.0b013e32832a9da7.

PMID:
19384192
16.

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.

Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group.

Curr Med Res Opin. 2009 Jan;25(1):65-75. doi: 10.1185/03007990802597951 .

PMID:
19210140
17.

A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis.

Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, Ko A, Cichanowitz N, Reicin AS.

Osteoarthritis Cartilage. 2007 Dec;15(12):1348-56. Epub 2007 Jul 16.

18.

Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies.

Quigley EM, Wald A, Fidelholtz J, Boivin M, Pecher E, Earnest D.

Clin Gastroenterol Hepatol. 2006 May;4(5):605-13.

PMID:
16678076
19.

Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.

Fidelholtz J, Smith W, Rawls J, Shi Y, Zack A, Rüegg P, Lefkowitz M.

Am J Gastroenterol. 2002 May;97(5):1176-81.

PMID:
12014724
20.

Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections.

Parish LC, Routh HB, Miskin B, Fidelholtz J, Werschler P, Heyd A, Haverstock D, Church D.

Int J Clin Pract. 2000 Oct;54(8):497-503.

PMID:
11198726

Supplemental Content

Loading ...
Support Center